Literature DB >> 8384810

Structure-activity relationships and modes of action of 9-anilinoacridines against chloroquine-resistant Plasmodium falciparum in vitro.

P Chavalitshewinkoon1, P Wilairat, S Gamage, W Denny, D Figgitt, R Ralph.   

Abstract

An in vitro investigation of the structure-activity profiles for a range of 9-anilinoacridines on drug-resistant Plasmodium falciparum is reported. C-3, 6-diamino substitution, low lipophilicity, and high pKa values substantially increased the activities of the 9-anilinoacridines tested. There appeared to be no correlation between DNA binding and antimalarial activity. 3,6-Diamino-1'-amino-9-anilinoacridine (compound 13) was the most active compound tested; it had a 50% inhibitory concentration of 25 nM. In vitro mammalian cell growth assays showed compound 13 to be one of the least cytotoxic 9-anilinoacridines (50% inhibitory concentration, 15 microM). Both compound 13 and the antimalarial drug pyronaridine inhibited the decatenation activity of P. falciparum DNA topoisomerase II at concentrations of 10 and 11 microM, respectively.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384810      PMCID: PMC187684          DOI: 10.1128/AAC.37.3.403

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  DNA topoisomerases as anticancer drug targets.

Authors:  E Schneider; Y H Hsiang; L F Liu
Journal:  Adv Pharmacol       Date:  1990

2.  Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues.

Authors:  G J Finlay; B C Baguley; K Snow; W Judd
Journal:  J Natl Cancer Inst       Date:  1990-04-18       Impact factor: 13.506

3.  Potential antitumor agents. 14. Acridylmethanesulfonanilides.

Authors:  B F Cain; R N Seelye; G J Atwell
Journal:  J Med Chem       Date:  1974-09       Impact factor: 7.446

Review 4.  Studies on a new antimalarial compound: pyronaridine.

Authors:  C Chang; T Lin-Hua; C Jantanavivat
Journal:  Trans R Soc Trop Med Hyg       Date:  1992 Jan-Feb       Impact factor: 2.184

5.  Purification and characterization of Plasmodium berghei DNA topoisomerases I and II: drug action, inhibition of decatenation and relaxation, and stimulation of DNA cleavage.

Authors:  J F Riou; M Gabillot; M Philippe; J Schrevel; G Riou
Journal:  Biochemistry       Date:  1986-04-08       Impact factor: 3.162

6.  Potential antitumor agents. 17. 9-Anilino-10-methylacridinium salts.

Authors:  B F Cain; G J Atwell; W A Denny
Journal:  J Med Chem       Date:  1976-06       Impact factor: 7.446

7.  The fate of N1'-methanesulphonyl-N4'-(9-acridinyl)-3'-methoxy-2',5'-cyclohexadiene- 1',4'-diimine (m-AQDI), the primary oxidative metabolite of amsacrine, in transformed Chinese hamster fibroblasts.

Authors:  M A Robbie; B D Palmer; W A Denny; W R Wilson
Journal:  Biochem Pharmacol       Date:  1990-05-01       Impact factor: 5.858

8.  Travellers' malaria.

Authors:  R Steffen; R H Behrens
Journal:  Parasitol Today       Date:  1992-02

9.  Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells.

Authors:  L Yang; T C Rowe; L F Liu
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

10.  In vitro study of anticancer acridines as potential antitrypanosomal and antimalarial agents.

Authors:  D Figgitt; W Denny; P Chavalitshewinkoon; P Wilairat; R Ralph
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

View more
  15 in total

1.  Antimalarial 9-anilinoacridine compounds directed at hematin.

Authors:  Saranya Auparakkitanon; Wilai Noonpakdee; Raymond K Ralph; William A Denny; Prapon Wilairat
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

2.  Targeting of hematin by the antimalarial pyronaridine.

Authors:  Saranya Auparakkitanon; Soebsakul Chapoomram; Kannika Kuaha; Thamrong Chirachariyavej; Prapon Wilairat
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  The gene encoding topoisomerase II from Plasmodium falciparum.

Authors:  S Cheesman; S McAleese; M Goman; D Johnson; P Horrocks; R G Ridley; B J Kilbey
Journal:  Nucleic Acids Res       Date:  1994-07-11       Impact factor: 16.971

4.  In vivo monitoring of intracellular ATP levels in Leishmania donovani promastigotes as a rapid method to screen drugs targeting bioenergetic metabolism.

Authors:  J R Luque-Ortega; O M Rivero-Lezcano; S L Croft; L Rivas
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 5.  DNA topoisomerases in apicomplexan parasites: promising targets for drug discovery.

Authors:  Carlos García-Estrada; Christopher Fernández Prada; Celia Fernández-Rubio; Francisco Rojo-Vázquez; Rafael Balaña-Fouce
Journal:  Proc Biol Sci       Date:  2010-03-03       Impact factor: 5.349

6.  Bioanalytical Screening of Riboflavin Antagonists for Targeted Drug Delivery - A Thermodynamic and Kinetic Study.

Authors:  Anna Plantinga; Amanda Witte; Ming-Hsin Li; Andrew Harmon; Seok Ki Choi; Mark M Banaszak Holl; Bradford G Orr; James R Baker; Kumar Sinniah
Journal:  ACS Med Chem Lett       Date:  2011-05-12       Impact factor: 4.345

7.  The Antimalarial Drug Pyronaridine Inhibits Topoisomerase II in Breast Cancer Cells and Hinders Tumor Progression In Vivo.

Authors:  Paulina J Villanueva; Denisse A Gutierrez; Lisett Contreras; Karla Parra; Aldo Segura-Cabrera; Armando Varela-Ramirez; Renato J Aguilera
Journal:  Clin Cancer Drugs       Date:  2021-02-19

8.  Absorption, distribution, excretion, and pharmacokinetics of 14C-pyronaridine tetraphosphate in male and female Sprague-Dawley rats.

Authors:  Sang Hyun Park; Kannampalli Pradeep
Journal:  J Biomed Biotechnol       Date:  2010-03-31

9.  Effect of structure on antibiotic action of new 9-(ethylthio)acridines.

Authors:  K Nesmĕrák; M Pospisek; B Zikánová; I Nĕmec; J Barbe; J Gabriel
Journal:  Folia Microbiol (Praha)       Date:  2002       Impact factor: 2.099

10.  Review of pyronaridine anti-malarial properties and product characteristics.

Authors:  Simon L Croft; Stephan Duparc; Sarah J Arbe-Barnes; J Carl Craft; Chang-Sik Shin; Lawrence Fleckenstein; Isabelle Borghini-Fuhrer; Han-Jong Rim
Journal:  Malar J       Date:  2012-08-09       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.